Management ChangeJun 11, 2026, 08:31 AM
Zevra Therapeutics CMO Adrian Quartel to Step Down July 3
AI Summary
Zevra Therapeutics announced that its Chief Medical Officer, Adrian Quartel, M.D., will be stepping down from his position due to personal reasons, effective July 3, 2026. Dr. Quartel will continue to support the company as a consultant through December 31, 2026, to ensure a seamless transition while Zevra searches for a new CMO. The company expressed gratitude for his contributions, including the FDA approval and launch of MIPLYFFA, and noted that its regulatory milestones, such as the arimoclomol MAA and celiprolol Phase 3 trial, remain on track.
Key Highlights
- CMO Adrian Quartel to step down from Zevra Therapeutics effective July 3, 2026.
- Dr. Quartel will continue to support Zevra in a consulting capacity through December 31, 2026.
- Company is conducting a search for its next Chief Medical Officer.
- Zevra's arimoclomol MAA for Niemann-Pick disease type C is under review by the European Medicines Agency.
- Company is conducting a Phase 3 trial of celiprolol for Vascular Ehlers-Danlos Syndrome.
- Zevra plans further dialogue with the U.S. FDA in H2 2026 for celiprolol development acceleration.
Price Impact
More from ZVRA